ht-29細(xì)胞

細(xì)胞名稱： 人結(jié)腸癌細(xì)胞（STR鑒定正確）

細(xì)胞別稱：HT 29; HT29； ht-29細(xì)胞

貨號(hào)：TCH-C213

規(guī)格：1×10?cells |  T25 培養(yǎng)瓶

價(jià)格：1500元   (干冰運(yùn)輸需另加200元干冰費(fèi))

種屬來(lái)源：人

組織來(lái)源：結(jié)直腸

特    征：結(jié)直腸癌

細(xì)胞形態(tài)：上皮細(xì)胞樣

生長(zhǎng)特性：貼壁生長(zhǎng)

培養(yǎng)體系：McCoy's 5A+10%FBS+1%P/S

配套培養(yǎng)基貨號(hào)：TCH-G213

傳代比例：1:3-1:6，每2-3天換液一次

傳代周期：48-72 h

培養(yǎng)條件：氣相：95%空氣+5%CO2，溫度：37℃

凍存條件：60%基礎(chǔ)培養(yǎng)基+30%FBS+10%DMSO，液氮儲(chǔ)存

質(zhì)量檢測(cè)：細(xì)菌、真菌、支原體檢測(cè)均為陰性

 ht-29細(xì)胞是1964年由FoghJ用移植培養(yǎng)方法和含15%FBS的F12培養(yǎng)液從原發(fā)性腫瘤分離的。近來(lái)，已建株的培養(yǎng)細(xì)胞用含血清的McCoy's5a培養(yǎng)基培養(yǎng)。該細(xì)胞系在裸鼠中成瘤，也能在類固醇處理的地鼠中成瘤。該細(xì)胞可合成IgA、CEA、TGFβ結(jié)合蛋白和黏液素；表達(dá)受體，但沒(méi)有檢測(cè)到血漿酶原活性；不表達(dá)CD4，但細(xì)胞表面表達(dá)半乳糖神經(jīng)酰胺（HIV的可能替代受體）。該細(xì)胞系癌基因c-myc、K-ras、H-ras、N-ras、Myb、sis、fos陽(yáng)性；p53基因過(guò)表達(dá)，并且在273位密碼子處發(fā)發(fā)生G。

     蘇州阿爾法生物除了提供細(xì)胞系購(gòu)買，細(xì)胞株購(gòu)買，pc12細(xì)胞株，肺癌細(xì)胞株，ht-29細(xì)胞，血管內(nèi)皮細(xì)胞株，肝癌細(xì)胞株，腫瘤細(xì)胞株，胃癌細(xì)胞株，hela細(xì)胞株，胰島細(xì)胞株，s180細(xì)胞株，hela細(xì)胞株，動(dòng)物細(xì)胞，干細(xì)胞外，還提供MEM培養(yǎng)基,DMEM,F12培養(yǎng)基,RPMI培養(yǎng)基等基礎(chǔ)培養(yǎng)基，干細(xì)胞培養(yǎng)基,培養(yǎng)基添加劑,間充質(zhì)干細(xì)胞培養(yǎng)基 ,培養(yǎng)基,低血清培養(yǎng)基,胎牛血清,雞血清等細(xì)胞培養(yǎng)試劑。

參考文獻(xiàn)：

"Didier ES, et al. Characterization of Encephalitozoon (Septata) intestinailis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J. Eukaryot. Microbiol. 43: 34-43, 1996. PubMed: 8563708

Fogh J. Human tumor cells in vitro. New York: Plenum Press; 1975.

Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642

Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed:

Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832

Fantini J, et al. Human colon epithelial cells productively infected with human immunodeficiency virus show impaired differentiation and altered secretion. J. Virol. 66: 580-585, 1992. PubMed: 1727501

Butzow R, et al. A 60-kD protein mediates the binding of transforming growth factor-beta to cell surface and extracellular matrix proteoglycans. J. Cell Biol. 122: 721-727, 1993. PubMed: 8335695

Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

Hanski C, et al. Tumorigenicity, mucin production and AM-3 epitope expression in clones selected from the HT-29 colon carcinoma cell line. Int. J. Cancer 50: 924-929, 1992. PubMed: 1372882

Reiter LS, et al. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int. J. Cancer 53: 444-450, 1993. PubMed: 8381394

Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498

Shabahang M, et al. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53: 3712-3718, 1993. PubMed: 8393379"